RxDoctor Payments Data

Bilal Nazif, DO

Internal Medicine · Mission, TXNPI 1194170282

Payments from drug & device makers

$2,029in general payments, 2019–2025

Across 109 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$385
  • Lilly USA, LLC$257
  • AbbVie$184
  • AstraZeneca$142
  • Otsuka America Pharmaceutical, Inc.$131
  • Amgen$127
  • plus $803 from 15 others

What the payments were for

  • Food & beverage$2,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,029 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$61,537
Medicare patients
99
Services billed
1,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide205$211,498
FarxigaDapagliflozin Propanediol155$165,288
MounjaroTirzepatide105$122,553
RybelsusSemaglutide28$50,016
JardianceEmpagliflozin42$44,941
TrulicityDulaglutide26$40,685
LinzessLinaclotide46$38,805
JanuviaSitagliptin Phosphate27$34,312
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$31,827
XareltoRivaroxaban22$30,778
VraylarCariprazine Hcl21$28,479
EliquisApixaban24$26,537
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$25,590
VascepaIcosapent Ethyl37$22,229
ProliaDenosumab12$19,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$385$261,514233 claims
AstraZenecaFarxiga, Breztri Aerosphere$142$190,878192 claims
Lilly USA, LLCMounjaro, Trulicity$257$163,238131 claims
AbbVieLinzess, Vraylar$184$67,28467 claims
MerckJanuvia, Belsomra$20$39,21138 claims
GSKTrelegy Ellipta$88$31,82737 claims
Johnson & JohnsonXarelto$56$30,77822 claims
PfizerEliquis$78$26,53724 claims
AmgenProlia$127$19,64012 claims
NovartisEntresto$87$13,68516 claims
BayerKerendia$45$6,85811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Mission

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →